


SB-221284

Cat. No.:	HY-103155
CAS No.:	196965-14-7
Molecular Formula:	C ₁₆ H ₁₄ F ₃ N ₃ OS
Molecular Weight:	353.36
Target:	5-HT Receptor
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	SB 221284 is a selective 5-HT _{2C/2B} receptor antagonist with pK _i values are 6.4, 7.9 and 8.6 for 5-HT _{2A} , 5-HT _{2B} and 5-HT _{2C} receptors, respectively. SB 221284 can be used for the research of neurological disease ^[1] .																		
IC₅₀ & Target	5-HT _{2A} Receptor 6.4 (pKi)	5-HT _{2B} Receptor 7.9 (pKi)	5-HT _{2C} Receptor 8.6 (pKi)																
In Vivo	<p>SB 221284 (0.1~1 mg/kg, i.p.) pre-treatment doses shows to block mCPP induced hypolocomotion, significantly enhances the hyperactivity induced by phencyclidine or MK-801^[1].</p> <p>SB 221284 (1 mg/kg, i.p.) significantly enhances the magnitude and duration of the increase induced by phencyclidine^[1]</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Male Sprague Dawley rats (250–360 g)^[1]</td> </tr> <tr> <td>Dosage:</td> <td>0.1~1 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>i.p.</td> </tr> <tr> <td>Result:</td> <td>Pre-treatment doses showed to block mCPP induced hypolocomotion, significantly enhanced the hyperactivity induced by phencyclidine or MK-801.</td> </tr> </table> <table border="1"> <tr> <td>Animal Model:</td> <td>Male Sprague Dawley rats (250–360 g)^[1]</td> </tr> <tr> <td>Dosage:</td> <td>1 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>i.p.</td> </tr> <tr> <td>Result:</td> <td>Significantly enhanced the magnitude and duration of the increase induced by phencyclidine.</td> </tr> </table>			Animal Model:	Male Sprague Dawley rats (250–360 g) ^[1]	Dosage:	0.1~1 mg/kg	Administration:	i.p.	Result:	Pre-treatment doses showed to block mCPP induced hypolocomotion, significantly enhanced the hyperactivity induced by phencyclidine or MK-801.	Animal Model:	Male Sprague Dawley rats (250–360 g) ^[1]	Dosage:	1 mg/kg	Administration:	i.p.	Result:	Significantly enhanced the magnitude and duration of the increase induced by phencyclidine.
Animal Model:	Male Sprague Dawley rats (250–360 g) ^[1]																		
Dosage:	0.1~1 mg/kg																		
Administration:	i.p.																		
Result:	Pre-treatment doses showed to block mCPP induced hypolocomotion, significantly enhanced the hyperactivity induced by phencyclidine or MK-801.																		
Animal Model:	Male Sprague Dawley rats (250–360 g) ^[1]																		
Dosage:	1 mg/kg																		
Administration:	i.p.																		
Result:	Significantly enhanced the magnitude and duration of the increase induced by phencyclidine.																		

REFERENCES

[1]. Hutson PH, et al. Activation of mesolimbic dopamine function by phencyclidine is enhanced by 5-HT(2C/2B) receptor antagonists: neurochemical and behavioural

studies. *Neuropharmacology*. 2000;39(12):2318-2328.

[2]. Bromidge SM, et al. Novel and selective 5-HT_{2C}/2B receptor antagonists as potential anxiolytic agents: synthesis, quantitative structure-activity relationships, and molecular modeling of substituted 1-(3-pyridylcarbamoyl)indolines. *J Med Chem*. 1998;41(10):1598-1612.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA